[ Skip to Main Content ]
COVID-19: How We’re Responding

Our Work

And you can join the conversation.

On Thursday 10 February (2pm CET), we'll host a Twitter Chat with several contributors and other organisations who have made the FAIR SHARE Commitment to explore the themes of the publication further.

Bring your questions, comments and ideas!

Working towards #genderequality is a collective journey.

That's why we contributed to #LeadingForChange, a collection of organizational case studies put together by @fair_wl exploring #FeministLeadership, organizational change and more.

Find it here: https://fairsharewl.org/project/leading-for-change/

We’re #hiring an Asst. Controller who supports the Controller & CFAO and supervises general accounting, accounts payable & receivable roles. Location negotiable: Washington, DC, preferred. Salary: $125-135k annually, benefits in posting. Apply ➡️ http://ow.ly/3o7W50HAQRz

Raising a glass to Roe v. Wade’s 49th anniversary. I don’t have a lot of hope that we’ll get to celebrate its 50th . Thanks to those who provide, facilitate, & fund abortions. Respect to those who have chosen/may later choose abortion. Power to those working for repro justice.

Last year, Nigerian medical student @ebereillustrate’s image of a Black fetus in the womb went viral, highlighting the need for #diversity in medical illustration. Now, some of his illustrations will be published in a clinical handbook!
http://ow.ly/nJvB50HzqIt

Episode 2 of this season’s Inside The FP Story podcast features programs from @EngenderHealth @CHAI_health and Bangladesh Sheikh Mujib Medical University, integrating #familyplanning with other health areas and settings. https://hubs.ly/Q012tTYJ0

Great news out of #Ghana 🇬🇭! Starting this month, long-term contraceptive methods will be available free of charge in the country, improving access to contraception for millions of women. 🙌

Read more ➡️ http://ow.ly/vuKH50Hxw6q

We’re excited to have @EngenderHealth accept the #WeTrustYouthChallenge, and make their commitment to collectively better the ways of working with young people meaningfully!

Are you ready to join us? Find out more and accept the challenge, now: http://WeTrustYouth.org

Episode 2 of this season’s Inside The FP Story podcast by @fprhknowledge & @ibp_network features an interview with our Senior Technical Advisor Anna Temba discussing mobile family planning outreach & service integration in #Tanzania. Listen now! ➡️ http://ow.ly/B4QU50HxvIr

On January 20, Priyanka Kochar, programs manager for EngenderHealth’s India country office, will take part in a webinar, hosted by @ShareNetIntl, launching the BLOOM (Buy-in and Learning through Outcomes of MYP) campaign. Register today! ➡️ https://share-netinternational.org/events/bloom-campaign-webinar-launch/

Load More...

Eclampsia and Pre-Eclampsia

Giving birth should be a time for celebration, but for more than half a million women each year—one every 90 seconds—pregnancy and childbirth end in death and mourning. Ninety-nine percent of these deaths occur in developing countries, and nearly all are preventable.

One of the leading causes of maternal death is pre-eclampsia—the rapid elevation of blood pressure during pregnancy—which, if untreated, can lead to seizures (eclampsia), kidney and liver damage, and ultimately, death. Eclampsia and severe pre-eclampsia claim the lives of an estimated 63,000 women each year, as well as the lives of many of their babies.  

A Ready Solution
The World Health Organization recognizes and recommends injectable magnesium sulfate—also known as Epsom salts—as the safest, most effective, and lowest-cost medication for treating pre-eclampsia and eclampsia. Magnesium sulfate is the standard treatment for these conditions in the developed world and has been for 20 years. Less-effective and riskier medications (such as diazepam and phenytoin), however, are still widely used in developing countries—if any treatment is available at all.

 

OUR COMMITMENT
We commit to reducing maternal mortality with magnesium sulfate in India, Mexico, and Nigeria. Through training, advocacy, and education, we will increase access to the lifesaving treatment for pre-eclampsia and eclampsia, leading causes of maternal mortality.

 

 

Clinton Global Initiative Commitment
This disparity must end. EngenderHealth, the University of Oxford, and the John D. & Catherine T. MacArthur Foundation are making a joint commitment as part of the Clinton Global Initiative to expand access to magnesium sulfate by:

  • Training health professionals through web-based interactive programs on when and how to administer magnesium sulfate
  • Advocating for magnesium sulfate to be part of every developing country’s list of essential drugs
  • Helping develop and/or reinforce national protocols mandating magnesium sulfate as the preferred treatment for pre-eclampsia and eclampsia
  • Ensuring the availability of magnesium sulfate in hospitals

Call to Action
In 2007, EngenderHealth and the University of Oxford brought together leading scientists, advocates, researchers, and representatives of the WHO, UNICEF, United Nations agencies, and national ministries of health from around the world to identify barriers to the availability and use of magnesium sulfate to treat pre-eclampsia and eclampsia. This historic gathering of global public health experts identified the primary barriers to be a lack of national guidelines, a shortage of educated and trained health care professionals, and scarce supplies of magnesium sulfate.

Based on these conclusions, EngenderHealth and the University of Oxford developed a “Call to Action” and report that called on policy makers and ministers of health to make pre-eclampsia and eclampsia a higher priority and to set national guidelines for treatment and care based on WHO guidelines. Decision makers and international and national health organizations and agencies were also urged to help make magnesium sulfate more available and affordable.

The full report, Balancing the Scales: Expanding Treatment for Pregnant Women with Life-Threatening Hypertensive Conditions in Developing Countries, is available for download (PDF, 316KB), as is the International Call to Action (PDF, 27KB).

Share this page: